Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 70

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 70
---
 $500,000. In accordance with ASC 855-10, Subsequent Events, the Company evaluated this event under ASC 855-10-25-1
and determined that it represents a Type I subsequent event (recognized subsequent event) because the sale provided additional evidence
about conditions that existed at the balance sheet date. Accordingly, the Company determined that the fair value of the equity securities
on the date of the Fourth Securities Purchase Agreement of April 21, 2025 and June 30, 2025 was equal to $500,000.

30

ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The
following Management’s Discussion and Analysis of Financial Condition and Results of Operations provides information that CERo
Therapeutics Holdings, Inc. (“the Company”) management believes is relevant to an assessment and understanding of its results
of operations and financial condition. The discussion should be read together with (i) the Company’s unaudited condensed consolidated
financial statements and related notes that are presented above and (ii) the Company’s audited consolidated financial statements
and related notes and management’s discussion and analysis of financial condition and results of operations included in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (the “SEC”)
on April 15, 2025. This Management’s Discussion and Analysis of Financial Condition and Results of Operations may contain forward-looking
statements based upon current expectations that involve risks and uncertainties. Actual results may differ materially from those anticipated
in these forward-looking statements resulting from various factors. Please see “Cautionary Note Regarding Forward Looking Statements”
and “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the subsequent
Quarterly Report on Form 10-Q as filed with the SEC. Unless the context otherwise requires, references in this section to “Predecessor”
is intended to mean the business and operations of CERo Therapeutics, Inc. prior to the Merger.

Overview

CERo
Therapeutics, Inc. (the “Predecessor”) was incorporated in Delaware on September 23, 2016, and is based in South San Francisco,
California. Predecessor was focused on developing its therapeutic platform to genetically engineer human immune cells to fight cancer
and did not begin clinical development or product commercialization. The Company